Annual report pursuant to Section 13 and 15(d)

Agreements (Details)

v2.4.0.8
Agreements (Details) (USD $)
12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended 84 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Nov. 30, 2009
Reliable Supply Agreement [Member]
Dec. 31, 2013
Reliable Supply Agreement [Member]
Dec. 31, 2012
Reliable Supply Agreement [Member]
Dec. 31, 2011
Reliable Supply Agreement [Member]
May 31, 2013
Nordion Supply Agreement [Member]
Dec. 31, 2013
Nordion Supply Agreement [Member]
Aug. 31, 2013
PETNET Supply Agreement [Member]
Dec. 31, 2013
PETNET Supply Agreement [Member]
Sep. 30, 2013
OsoBio Supply Agreement [Member]
Dec. 31, 2013
OsoBio Supply Agreement [Member]
Apr. 30, 2008
Research And Development Agreement [Member]
Jan. 31, 2002
Research And Development Agreement [Member]
Apr. 30, 2008
Research And Development Agreement [Member]
Minimum [Member]
Jan. 31, 2002
Research And Development Agreement [Member]
Minimum [Member]
Dec. 31, 2013
Employment Agreement [Member]
Minimum [Member]
Dec. 31, 2013
Employment Agreement [Member]
Maximum [Member]
Dec. 31, 2013
Astra Zeneca Agreement [Member]
Dec. 31, 2012
Astra Zeneca Agreement [Member]
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
Dec. 31, 2012
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
Dec. 31, 2012
Astra Zeneca Agreement [Member]
Maximum [Member]
Milestone Payments Based On Receipt Of Certain Regulatory Approvals And Initiation Of Commercial Sales Of Licensed Product [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Dec. 31, 2013
Alseres Pharmaceuticals Inc [Member]
Dec. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Alseres Milestone Payments Based On Product Registration Or Commercial Sales [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Milestone Payments Maximum [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Maximum [Member]
Dec. 31, 2012
Cardiosonix [Member]
Dec. 31, 2013
Cardiosonix [Member]
Dec. 31, 2013
Cardiosonix [Member]
Minimum [Member]
Dec. 31, 2013
Cardiosonix [Member]
Maximum [Member]
Dec. 31, 2013
Lymphoseek License Agreement [Member]
Dec. 31, 2012
Lymphoseek License Agreement [Member]
Dec. 31, 2011
Lymphoseek License Agreement [Member]
Dec. 31, 2013
Lymphoseek Expanded License Agreement [Member]
Dec. 31, 2012
Lymphoseek Expanded License Agreement [Member]
Dec. 31, 2011
Lymphoseek Expanded License Agreement [Member]
Jan. 31, 2006
Cira License Agreement [Member]
Dec. 31, 2013
Cira License Agreement [Member]
Agreements [Line Items]                                                                                      
Purchases under manufacture and supply agreement         $ 666,000 $ 939,000 $ 544,000   $ 771,000   $ 1,400,000   $ 1,200,000                                                            
Purchase orders issued         0       314,000   1,400,000   0                                                            
License fee                           25,000 25,000               5,000,000.0                                     5,000  
License maintenance fee                           25,000 25,000                                                        
Royalty on net sales of licensed products , percentage                           5.00% 5.00%                                     3.00% 5.00%                
Research and development 23,710,183 16,890,482 15,154,365                                 5,000 14,000 5,000,000         366,000 1,800,000               273,000 33,000 98,000 29,000 31,000 28,000 100,000  
Common stock, shares issued 135,919,423 113,018,772                                               300,000     950,000 1,150,000.00                          
Contingent milestone payment                                               6,500,000.0 11,000,000.0       2,500,000   2,900,000                        
Royalty percentage on grant revenues                                                                     300.00%                
Royalty expense                               25,000 25,000                             84,000                     100,000
Percentage of sublicense fees (royalties)                           50.00% 50.00%                                                        
Accrued royalties                                                                 0                    
Maximum contingent liability                                     3,100,000                                                
Ratio of entitled salary                                   1.1 2.1                                                
Sublicense execution payment, cash paid                                                   175,000                                  
Grants received from Office of the Chief Scientist                                                               $ 775,000                      
Initial Term               3 years   3 years                                                                  
Resolution Term       60 days       30 days   30 days   60 days                                                              
Automatic Renewal Date                   1 year   2 years                                                              
Notice Period               180 days   60 days   12 months